GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN TYPE 2 DIABETES MELLITUS (T2DM): DATA FROM A REAL WORLD STUDY IN SPAIN

被引：0
|
作者：
Norrbacka, K. [1 ]
Sicras-Mainar, A. [2 ]
Hernandez, I [3 ]
Tofe-Povedano, S. [4 ]
Diaz Cerezo, S. [5 ]
Artime, E. [5 ]
Lebrec, J. [6 ]
Romera, I [5 ]
机构：
[1] Eli Lilly & Co, Helsinki, Finland
[2] Real Life Data SLU, Barcelona, Spain
[3] Real Life Data SLU, Madrid, Spain
[4] Univ Hosp Son Espases Palma de Mallorca, Palma De Mallorca, Spain
[5] Lilly Spain, Alcobendas, Spain
[6] HaaPACS GmbH, Schriesheim, Germany
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB119
引用
收藏
页码：S594 / S594
页数：1
相关论文
共 50 条
  • [31] The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study
    Gameil, Mohammed Ali
    Yousef, Elshahat Ali Ahmed Mohamed
    Marzouk, Rehab Elsayed
    Emara, Mohamed H.
    Abdelkader, Abeer H.
    Salama, Rasha Ibrahim
    DIABETOLOGY & METABOLIC SYNDROME, 2024, 16 (01):
  • [32] Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future
    Filipe Ferrari
    Rafael S. Scheffel
    Vítor M. Martins
    Raul D. Santos
    Ricardo Stein
    American Journal of Cardiovascular Drugs, 2022, 22 : 363 - 383
  • [33] Glucagon-like peptide-1 receptor agonists for improving cardiorenal outcomes in type 1 diabetes mellitus?
    Djordje S. Popovic
    Anca Pantea Stoian
    Nikolaos Papanas
    Endocrine, 2023, 80 : 232 - 233
  • [34] Effect of glucagon-like peptide-1 receptor agonists in subjects with type 2 diabetes mellitus: A meta-analysis
    Qian, Weiyun
    Liu, Fei
    Yang, Qichao
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2021, 46 (06) : 1650 - 1658
  • [35] Adjunctive Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Type 1 Diabetes Mellitus
    Harris, Kira B.
    Boland, Cassie L.
    PHARMACOTHERAPY, 2016, 36 (09): : 1011 - 1020
  • [36] Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li, Yixing
    Rosenblit, Paul D.
    CURRENT CARDIOLOGY REPORTS, 2018, 20 (11)
  • [37] Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease
    Desai, Aakash
    Petrov, Jessica
    Hashash, Jana G.
    Patel, Harsh
    Brahmbhatt, Bhaumik
    Kochhar, Gursimran S.
    Farraye, Francis A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (05) : 620 - 632
  • [38] Cardioprotective properties of glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: A systematic review
    Widiarti, Wynne
    Sukmajaya, Alverina Cynthia
    Nugraha, David
    Alkaff, Firas Farisi
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2021, 15 (03) : 837 - 843
  • [39] Glucagon-like peptide-1 receptor agonists for improving cardiorenal outcomes in type 1 diabetes mellitus?
    Popovic, Djordje S. S.
    Stoian, Anca Pantea
    Papanas, Nikolaos
    ENDOCRINE, 2023, 80 (01) : 232 - 233
  • [40] Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future
    Ferrari, Filipe
    Scheffel, Rafael S.
    Martins, Vitor M.
    Santos, Raul D.
    Stein, Ricardo
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2022, 22 (04) : 363 - 383
12345